Menu
Currency
GWAS Study

Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci.

Ghouse J, Tragante V, Muhammad A et al.

35751511 PubMed ID
GWAS Study Type
78000 Participants
56 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

GJ
Ghouse J
TV
Tragante V
MA
Muhammad A
AG
Ahlberg G
SM
Skov MW
RD
Roden DM
JI
Jonsdottir I
AL
Andreasen L
LP
Lundegaard PR
TL
Trudsø LC
BK
Banasik K
BS
Brunak S
OS
Ostrowski SR
TC
Torp-Pedersen C
PO
Pedersen OV
SE
Sørensen E
KL
Køber L
IK
Iversen K
TU
Thorsteinsdottir U
TG
Thorgeirsson G
UH
Ullum H
GD
Gudbjartsson DF
MJ
Mosley JD
HH
Holm H
SK
Stefansson K
BH
Bundgaard H
OM
Olesen MS
Chapter II

Abstract

Summary of the research findings

Aims: To search for sequence variants associated with ACEi discontinuation and to test their association with ACEi-associated adverse drug reactions (ADRs).

33,959 European ancestry cases who discontinued ACEi, 44,041 European ancestry controls who continued ACEi treatment

Chapter III

Study Statistics

Key metrics and study information

78000
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.K., Iceland
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.